|
|||||
|
|
Reduction in short‐acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes |
|
| Authors: | Julio Rosenstock Thomas C. Blevins Richard M. Bergenstal Linda A. Morrow Yongming Qu Scott J. Jacober |
| Affiliation: | 1. Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas;2. Texas Diabetes and Endocrinology, Austin, Texas;3. International Diabetes Center at Park Nicollet, Minneapolis, Minnesota;4. Profil Institute for Clinical Research Inc., Chula Vista, California;5. Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana, USA |
| Abstract: | |
| Keywords: | hypoglycemia insulin glargine insulin peglispro short‐acting insulin type 1 diabetes mellitus |